Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Rectal cancer is one of the common malignant tumors of the digestive tract. Some patients
with rectal cancer are already advanced tumors when they are first diagnosed. At this time,
the tumor has local infiltration, the probability of recurrence and metastasis after surgical
resection is high, and even radical tumor resection cannot be performed. Neoadjuvant
chemotherapy and radiotherapy have become one of the important treatment methods for these
patients to increase the rate of radical tumor resection. However, a series of side effects
of neoadjuvant radiotherapy can even continue after the end of radiotherapy, and even
increase the incidence of postoperative complications. Superselective arterial interventional
chemotherapy has been widely used in preoperative neoadjuvant chemotherapy for various
tumors, and its efficacy in rectal cancer has also been confirmed. In addition, as a hot spot
in tumor treatment, tumor immunotherapy has shown exciting effects in the NICHE study of
neoadjuvant immunotherapy before colon cancer surgery. Moreover, Oxaliplatin is a classic
chemotherapeutic drug that induces Immunogenic cell death effects, which induce antitumor
immunity.
Therefore, in order to optimize the preoperative neoadjuvant therapy plan, we propose a
treatment method of superselective arterial chemoembolization combined with immunotherapy and
systemic chemotherapy, in order to obtain better preoperative conversion therapy effect and
reduce the adverse reactions of neoadjuvant therapy.
Phase:
Phase 2
Details
Lead Sponsor:
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Collaborator:
Second Affiliated Hospital, School of Medicine, Zhejiang University